Cargando…
Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19
Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in diseas...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480897/ https://www.ncbi.nlm.nih.gov/pubmed/34587192 http://dx.doi.org/10.1371/journal.pone.0257965 |
_version_ | 1784576565840969728 |
---|---|
author | Sell, Stacy L. Prough, Donald S. Weisz, Harris A. Widen, Steve G. Hellmich, Helen L. |
author_facet | Sell, Stacy L. Prough, Donald S. Weisz, Harris A. Widen, Steve G. Hellmich, Helen L. |
author_sort | Sell, Stacy L. |
collection | PubMed |
description | Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction. |
format | Online Article Text |
id | pubmed-8480897 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-84808972021-09-30 Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 Sell, Stacy L. Prough, Donald S. Weisz, Harris A. Widen, Steve G. Hellmich, Helen L. PLoS One Research Article Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction. Public Library of Science 2021-09-29 /pmc/articles/PMC8480897/ /pubmed/34587192 http://dx.doi.org/10.1371/journal.pone.0257965 Text en © 2021 Sell et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Sell, Stacy L. Prough, Donald S. Weisz, Harris A. Widen, Steve G. Hellmich, Helen L. Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title | Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title_full | Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title_fullStr | Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title_full_unstemmed | Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title_short | Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19 |
title_sort | leveraging publicly available coronavirus data to identify new therapeutic targets for covid-19 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8480897/ https://www.ncbi.nlm.nih.gov/pubmed/34587192 http://dx.doi.org/10.1371/journal.pone.0257965 |
work_keys_str_mv | AT sellstacyl leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT proughdonalds leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT weiszharrisa leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT widensteveg leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 AT hellmichhelenl leveragingpubliclyavailablecoronavirusdatatoidentifynewtherapeutictargetsforcovid19 |